Inotuzumab

• CAT Number: I042524
• CAS Number: 1660159-36-3
• Purity: ≥95%

Inotuzumab (Cat No.: I042524) is an antibody-drug conjugate composed of a humanized anti-CD22 monoclonal antibody linked to calicheamicin, a potent cytotoxic agent. It specifically targets CD22, a surface antigen expressed on B cells, making it effective in treating B-cell malignancies. Approved as Inotuzumab ozogamicin for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), it delivers the cytotoxin directly to cancer cells, minimizing systemic toxicity. This targeted approach enhances efficacy while reducing off-target effects, representing a significant advancement in hematologic cancer therapy.

Reference

[1]. Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.
[Content Brief]